Showing posts with label Market Research Reports. Show all posts
Showing posts with label Market Research Reports. Show all posts

Monday, 16 June 2014

Nutraceutical Ingredients Market is Expected to Reach USD 29.5 Billion Globally in 2017: Transparency Market Research

04:27 No comments
According to a new market report published by Transparency Market Research "Nutraceutical Ingredients Market - Global Industry Analysis, Market Size, Share, Growth And Forecast 2007 - 2017", global nutraceutical ingredients market is expected to be worth USD 20.8 billion in 2012 and is further expected to reach USD 29.5 billion in 2017, growing at a CAGR of 7.3% from 2012 to 2017. The body building segment is expected to be the largest segment at USD 9.5 billion in 2012. In the overall global market, Asia Pacific region is expected to maintain its lead position in terms of revenue till 2017. Asia Pacific is expected to enjoy 37.5% of global nutraceutical ingredients market revenue share in 2017 followed by North America.

Browse the Nutraceutical Ingredients Market report with full TOC athttp://www.transparencymarketresearch.com/nutraceutical-ingredients-market.html

Increasing number of clinical studies confirming the health benefits of nutraceuticals and their broad applications in food, beverages, dietary supplements, and pediatric and adult nutritional preparations has provided support for the growing use of nutraceutical ingredients. Moreover, faster growth in consumption of nutraceutical ingredients worldwide, especially in developing economies has boosted the growth of nutraceutical ingredient market. In addition, increasing economic prosperity in developing countries including India, China, Brazil, Mexico, Russia,South Africa, South Koreaand Poland will enable consumers to spend more on health and nutrition. This will boost the future growth of the nutraceutical ingredient market.


Major segments of nutraceutical ingredients market include Body building, weight control, diabetes control and pain relief. In 2011, body building was the largest segment followed by weight control. The controlling diabetes segment was the third largest segment, accounting for 16.5% revenue share in 2011.
Amino acids and soy-based ingredients segments of body building market witnessed healthy growth rate during the review period (from 2007 to 2011). The growth in amino acid & soy-based ingredient segment is largely attributed to increased trend of fitness in most of the developing nations. The protein and peptide segment is also expected to have steady growth rate because of growing demand for nutritional diet and proper physic all over the world.

Browse all Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

Nutraceutical ingredients presents opportunity for new entrants as well for existing players, due to the fact that most of the raw materials are abundant and product manufacturers are increasingly focusing on contract manufacturing outsourcing (CMO). Moreover, large product manufacturers are looking for backward integration, which will grow the competition into the market and will intern increase the market size of the nutraceutical ingredients.
This report is an effort to identify factors, which will be the driving force behind the nutraceutical ingredient market and its sub-markets over the next six years. The report provides extensive analysis of the nutraceutical industry, current market trends for better understanding of the nutraceutical ingredient market.

Read More

Enteric Disease Testing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019

02:34 No comments
According to a new market report published by Transparency Market Research, "Enteric Disease Testing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019," the global enteric disease testing market was valued at USD 3.1 billion in 2012 and is expected to grow at a CAGR of 2.4% from 2013 to 2019, to reach an estimated value of USD 3.6 billion in 2019.


Enteric diseases are major causes of morbidity and mortality worldwide. Developing socio-economic countries with poor drainage, sanitation along with overcrowding and low hygiene awareness account for majority of enteric infection incidences prevailing worldwide. These diseases usually exhibit mild symptoms but if not treated on time can lead to severe complications, resulting in death. In order to manage these diseases effectively, their early detection is essential. Various enteric diseases responsible for diarrhea, stomach pain, nausea, vomiting, anorexia, weight loss and fever are amebiasis, giardiasis, rotavirus infection, salmonellosis and shigellosis.


Traditionally, diagnosis of enteric infections relied on culture results of fecal specimen. Today, the world is witnessing a paradigm shift from culture to EIA (enzyme immunoassaya) and PCR (polymerase chain reaction) based tests owing to advantages associated with these newer testing methods. EIA and PCR tests offer enhanced sensitivity and specificity compared to culture tests and also give quick results. Globally the market for enteric disease testing is growing at a CAGR of 2.4% under the influence of rising awareness, demand for point of care testing and increasing application of molecular diagnostics. Use of molecular diagnostic products has made diagnosis easy and possible, even those strains which once seemed to be difficult and impossible. North America and Europe represent the largest regional markets because of rapid demand for molecular based diagnostics and due to high level of awareness among people about the diseases. C.difficile infection is one of the major causes of antibiotic related diarrhea in developed regions.

Browse all Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

Various epidemiological sources including CDC and American Association for Clinical Chemistry suggest that C.difficile infection incidence per 100,000 people has increased over the past few decades in United States. In developing nations, frequent travelling to regions where enteric diseases are epidemic is also one of the reasons driving the market growth. Asia-Pacific and Africa have been predicted to grow rapidly during the forecast period. In developing nations of Asia-pacific, Africa and Latin America, the market is also growing due to advent of rapid dipstick tests which can be applied by the patient themself. These regions associated with inadequate healthcare infrastructure do not possess substantial number of laboratories to perform laboratory based tests. Thus, rapid dipstick test kits being inexpensive and easy to use are widely accepted in these regions for managing enteric illness. Continuously improving economy and rising healthcare expenditure in these regions are also anticipated to drive the market. The market is also growing due to emergence of new strains; sources from Eurosurveillance suggest that the norovirus infection is increasing worldwide, including United Kingdom, the Netherlands, France, Japan and Australia due to emergence of new strain of genotype II.4 (GII.4) that is also known as Sydney strain.

Read More

Pain Management Therapeutics Market is expected to Decline to USD 29.47 Billion Globally by 2018: Transparency Market Research

00:02 No comments
According to a new market report published by Transparency Market Research "Pain Management Therapeutics Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018," in 2011, the global pain management therapeutics market was valued at USD 40.93 billion and is expected to decline at a CAGR of (5.5%) from 2012 to 2018, to reach an estimated value of USD 29.47 billion in 2018.

Browse the Pain Management Therapeutics Market Research report with full TOC at http://www.transparencymarketresearch.com/pain-management-therapeutics.html

The global pain management therapeutics market is expected to experience a decline in revenues at a CAGR of (5.5%) during the forecast period, mainly due to patent expirations of the leading branded drugs. Although the global incidence rates of cancer, diabetes and other debilitating diseases that cause various chronic pain conditions is on a rise, the decline in market revenue is inevitable due to generic incursion for the top pain management drugs. Moreover, lack of a strong pipeline of novel or combination drugs that could help restore the positive growth of the overall market is also expected to contribute to the overall decline in the global pain management therapeutics market.
Administration of analgesics is the first line of treatment for the management of acute as well as chronic pain conditions. Some of the factors driving the growth of this market include the favorable regulatory and healthcare reforms such as the U.S. Patient Protection and Affordable Care Act of 2010. Also, the economic and effective nature of treatment with therapeutics compared to other modes, such as neurostimulation devices and acupuncture, will continue to fuel the uptake of drugs in pain management.


The market for non-steroidal anti-inflammatory drugs (NSAIDs) accounted for the largest share by revenue in 2011, of the total pain management therapeutics market by therapeutic class. This class comprises of some of the oldest known painkillers such as diclofenac, ibuprofen and Aspirin (acetylsalicylic acid) which are now commonly available as over-the-counter (OTC) medications, globally. However, the patent expiry of Celebrex (celecoxib) in 2013 is expected to negatively impact the market with a decline in revenues post patent expiry. The class of other non-narcotic analgesics consists of acetaminophen, sold as OTC drugs in the names of Tylenol, Panadol and Excedrin, and is expected to record the highest CAGR of 3.1% during the forecast period.

Browse all Pharmaceutical Market Research Reports @http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

North America was the largest regional market by revenue in 2011, due to the presence of one or more branded drugs belonging to each therapeutic class. However, the region is expected to record the lowest CAGR due to the looming patent expiries of these brands.
The market for generic formulations accounted for a larger share of the overall pain management therapeutics market in 2011, as against branded formulations. The market for branded pharmaceuticals was highly fragmented in 2011, with Pfizer, Inc., Purdue Pharma LP and Eli Lilly & Co. contributing to over 80% of the total market revenue. Other important players in this market include Endo Health Solutions, AstraZeneca PLC, Johnson & Johnson, and Merck & Co., Inc.

Read More

Friday, 13 June 2014

Insulin Market Expected to Reach USD 32,346.7 Million in 2018 - Transparency Market Research

00:03 No comments
Insulin Market
According to a new market report published by Transparency Market Research "Insulin Market - Global and China Scenario, Trends, Industry Analysis, Size, Share and Forecast, 2011 - 2018" the global insulin market was worth USD 12,476.3 million in 2011 and is expected to reach USD 32,346.7 million in 2018, growing at a CAGR of 12% from 2011 to 2018. In the global market, China is expected to increase its share in the global insulin market to 10.2% by 2018.
The global insulin market is driven by rise in diabetic population worldwide. The world diabetes population was estimated at 366 million in the year 2011, and is expected to reach 552 million in 2030. It is estimated that diabetes accounts for 4.6 million deaths, with cases of people dying due to lack of insulin and not even being diagnosed.

This however, presents a huge supply demand deficit for insulin, with high growth potential in developing markets. The factors contributing to the insulin market growth also includes increase in global expenditure on healthcare, strong distribution network, and high scope in developing economies such as China and India.

Browse the full Insulin Market Report at http://www.transparencymarketresearch.com/insulin-market.html

It is estimated that worldwide, by year 2030, one in ten people will suffer from diabetes, giving rise to huge demand for insulin. China, being the most populous nation in the world, accounts for the largest share of the global diabetic population and eventually turns out as the most lucrative market for insulin manufacturers.

Get Free Sample Report at http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=259

The China insulin market is projected to grow at a CAGR twice that of the global insulin market. It was estimated at USD 723.8 million in 2011, and is projected to reach USD 3,299.1 million in the year 2018, growing at a CAGR of 24.6%. Currently, China accounts for 6.1% of the global insulin market in terms of volume, which was estimated at 22.4 tMU in 2011. The global insulin market by volume is projected to grow at a CAGR of 7.9% from 2012 - 2018.

Browse Blog http://tmrresearch.wordpress.com/

The global insulin market has continuously witnessed new advanced product types being introduced in the market by insulin manufacturers. The recent product type is modern insulin, which is a genetically engineered version of human insulin, and has been selectively modified to counter the issues associated with human insulin. Currently, modern insulin accounts for more than 76% of the global insulin market.
To meet the rising demand, global insulin manufacturers are not only augmenting existing production facilities, but also expanding their global presence to meet the supply demand gap. Leading insulin manufacturers are now focusing on reinforcing their market leadership in China. It includes key global and China insulin market players such as Novo Nordisk, Sanofi-Aventis, and Eli-Lilly. Together they account for more than 90% of the global insulin market share.

Browse all Pharmaceutical Research Report at http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html


This research is specially designed to estimate and analyze the demand and performance of the global and China insulin market in the current market scenario. This research provides in-depth analysis of insulin manufacturers, product sales, trend analysis by segments, and demand by geography. The report covers all the major product segments of the global and China insulin market and provides in-depth analysis, historical data and statistically refined forecast for the segments covered. 

Download PDF at Insulin Market - Global And China Industry Analysis, Size, Share, Growth, And Forecast 2011 - 2018
Read More

Thursday, 12 June 2014

Membrane Separation Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

01:26 No comments
According to a new market report published by Transparency Market Research "Membrane separation Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019," the global membrane separation market was valued at USD 19.0 billion in 2012 and is expected to grow at a CAGR of 10.8% from 2013 to 2019, to reach an estimated value of USD 39.2 billion in 2019.

Browse the full Membrane separation Market Report at http://www.transparencymarketresearch.com/membrane-separation-market.html

The increasing demand for clean processed water and mandatory government regulation to provide clean drinking water is propelling the water processing industry at present. Membrane separation is one of the most popular methods used for cleaning water. Shifting from chemical to physical treatments of water is also a major driver as chemical treatments are perceived as an environmentally unclean technology with associated disposal costs. Additional awareness of water scarcity has influenced the demand for water reuse in water stressed areas. Governments and municipal authorities are increasingly waking up to the effects of environmental degradation on the economy. Mandatory adherence of certain environmental standards by the national government such as the Clean Water Act especially in areas with water scarcity have influenced the demand for better water treatment technology, including membrane separation technology.


Worldwide industrial expansion and growing population are propelling the demand for better water treatment technology, providing growth opportunity for the overall market of membrane separation technology. Additionally, the oil and petroleum industry is well established in countries such as Italy and Germany which involve membrane separation technology for liquid separation. Membrane separation technology is majorly divided under four major processes, microfiltration, ultrafiltration, nanofiltration and reverse osmosis. Microfiltration dominates the market with more than 35% global market share. Whereas water & wastewater dominates the end-user market with 36% global market shares in terms of uses. The global membrane separation market grew from USD 19.0 billion in 2010 to USD 21.2 billion in 2013.
European membrane market is expected to reach USD 13.8 billion in 2019. In 2012 water & wastewater sector was the major end-user of membrane separation technology and is expected to increase at a CAGR of 11.1% during 2013-19. The membrane separation technology market is fragmented with several players in the market supplying membrane separation to the end-users in the market.


Membrane separation is used by various sectors such as water and wastewater treatment and industrial and healthcare sectors. Most of the companies produce different types of membrane products such as microfiltration, nanofiltration, ultrafiltration and reverse osmosis and sell them globally. Major companies that are operating globally and manufacturing all four products are Koch Membrane Systems Inc., Pall Corporation, Merck Millipore, 3M Company, Degremont SA, Dow Chemical Company, GEA Filtration, Nitto Denko Corporation, Époque Water Technologies and Veolia Environnement.

Read More

Thursday, 5 June 2014

Smoking Cessation and Nicotine De-addiction Products Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

04:09 No comments
Smoking Cessation and Nicotine De-addiction Products Market 
According to a new market report published by Transparency Market Research "Smoking Cessation and Nicotine De-addiction Products Market (Nicotine Gums, Patches, Lozenges, Inhalers, Sprays, Sublingual Tablets, Zyban, Chantix/Champix, E-cigarettes)- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019," the global smoking cessation and nicotine de-addiction productsmarket was valued at USD 5.1 billion in 2012 and is expected to grow at a CAGR of 18.7% from 2013 to 2019, to reach an estimated value of USD 16.02billion in 2019.

Smoking cessation is a process of discontinuing smoking achieved by the use of medication. It may also be coupled with assistance of healthcare professionals, counselling and psychotherapy. The demand for smoking cessation products is high and is continuously rising as it caters to the needs of people addicted to nicotine and rising healthcare awareness amongst the smokers. The global smoking cessation and nicotine de-addiction products market is segmented on the basis of product types available in the market. These include nicotine replacement therapy (NRT) products, drug therapy and e-cigarettes. This market is sustained by large number of people wanting to quit smoking.

Browse Global Smoking Cessation and Nicotine De-addiction Products Market with full TOC at http://www.transparencymarketresearch.com/smoking-cessation-nicotine-de-addiction-products.html

The nicotine patches and lozenges market is driven by its ease of use and non-prescription sale. Nicotine sprays and inhalers on the other hand are less preferred due to their high cost and less popularity. However, increased promotional activities and effective distribution is expected to boost their market growth in the near future. The major players in the NRT products market include Johnson and Johnson, GSK, Cipla and Novartis.
Smoking cessation drug therapy market is expected to witness a decline in revenue across the globe, by the end of the forecast period due to patent expiration of the key revenue generating drugs Zyban (bupropion)  in 2013 and Chantix/Champix (varenicline) in 2018 (which will impede market growth toa lower extent). The loss of patent and marketing exclusivity will lead to a drastic reduction in revenue and in turn provide an opportunity to generic manufacturers to launch their own versions of these brands. The leading players in the drug therapy market are GSK and Pfizer.


Geographically, North America dominates the global smoking cessation and nicotine de-addiction products market. The North American market for smoking cessation products was valued at USD 1,958.8 million in the year 2012. An increase in cigarette costs is expected to reduce smoking rates significantly, especially in adolescents. According to the CDC, a 10% rise in cigarettes cost can cut around 4% of young adults craving cigarette consumption. The European market held the second largest share worldwide, in 2012. WHO reports that European countries have widely adopted bans on tobacco advertising, promotion on national/international television and radio, billboards and outdoor advertising, local magazines and newspapers. However, some countries in Europe still lack in implementing measures of the WHO Framework Convention on Tobacco Control (FCTC).


Raising taxes to increase the cost of cigarettes can reduce tobacco use, cut smoking rates, and ultimately save lives. Smoking prevalence has been varying across the globe with many developing countries witnessing rapid increase in the prevalence rate, which will create huge health problems for the future if left unchecked. Demand for lifestyle drugs in emerging countries is witnessing rapid growth due to factors including growing health awareness, increase in population, and development of public healthcare systems, among others. This is driving people towards quitting smoking by adopting smoking cessation products. A study in the Eastern Mediterranean Health Journal, published in 2012, reported that nicotine containing medications are not available in one third of the developing countries, which include the Middle East and Africa. Moreover, accessibility of non-nicotine containing medications such as bupropion and varenicline is also extremely low. Increased attention and resources are needed to address lack of smoking cessation services as well as access to nicotine containing medications in these regions.

Read More

Thursday, 19 September 2013

Intrathecal Pumps Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast (2013 - 2019)

23:05 No comments
Intrathecal pumps classified under intrathecal drug delivery system are used to deliver small amounts of drug directly to the patient’s spinal fluid for relieving chronic back or spinal pain. This small programmed battery powered pump is surgically implanted under the subcutaneous tissue of the abdomen and is connected to a catheter tunneled to the site of spinal entry. Such devices consist of a computerized pain pump, a catheter and a reservoir which needs to be refilled every 1 to 3 months. In this drug delivery system, a lower dose of medication is required since the drug is delivered directly at the site of action and thus bypasses the phase of circulation throughout the body.


Intrathecal pumps market is categorized on the basis of the following applications:
  • Cancer Pain
  • Neuropathic Pain
  • Facial & Migraine Pain
  • Musculoskeletal Pain
  • Trauma
Globally, North America and western European countries dominates the intrathecal implant pumps market due to high prevalence of chronic or recurring pain in the general population, better reimbursement policies and increased awareness about healthcare and wellbeing in these regions. Emerging economies of Asia, Middle East and Latin America are predicted to incur the highest growth due to growing disease awareness and rising affordability in order to undertake such procedures.

Some of the key factors driving the growth of intrathecal pumps market are global growing elderly population and advances in technology. Increased incidences of cancer and diabetes, improved reimbursement policies and funding by government agencies, particularly in developing countries will further propel the intrathecal pumps market. However, high cost involved in implantation procedure of intrathecal pumps may pose a challenge to the growth of this market.

Some of the major companies contributing to the intrathecal pumps market include Baxter International Inc., Boston Scientific Corporation, Codman and Shurtleff, Inc., Hospira, Inc., Kimberly-Clark Corporation, St. Jude Medical, Inc., Medtronic, Inc., Advanced Bionics LLC, Medasys, Inc., Flowonix Medical, Inc., Smiths Medical ASD, Inc. and Stryker Corporation.


This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include 
  • North America 
  • Asia Pacific 
  • Europe
  • Rest of the World  
This report provides comprehensive analysis of 
  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for upcoming years 
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

About Us:

Transparency Market Research (TMR) is a market intelligence company providing global business research reports and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers.

TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources along with various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information which is indispensable for businesses to sustain their competitive edge.

Contact Us:

CORPORATE OFFICE:
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States

Tel: +1-518-618-1030
Read More

Wednesday, 11 September 2013

Global Anti-Migraine Drugs Market - Industry Analysis, Size, Share, Growth, Trends and Forecast (2013 - 2019)

23:13 No comments
Antimigraine drugs are the therapeutic agents indicated to use against migraine headaches. Migraine is characterized by recurrent attacks of moderate to severe headaches along with other nervous system symptoms. Migraine is more common in women than men, majorly due to the fluctuations in the harmone levels. According to a Medline article, around 12% of the U.S. population suffers from migraine headaches. The two major types of migraine are classic and common. Classic migraine is characterized by sudden change in eye sight and experience partial blindness or double vision. On the other hand common migraine patients witness sudden headaches on one or both the sides of the head. 


Migraine has a serious social and economic impact; According to National Headache Foundation migraine sufferers experience a loss in more than 157 million work days every year. Migraines cause both personal and professional disturbances and add to the overall healthcare costs to a nation. The treatment of migraine headaches is facilitated by administration of preventive medications, to avoid the migraine attacks and abortive medications to relieve the intense and periodic pain. 

The market for anti-migraine drugs witnesses an upward growth curve majorly due to increasing incidences of migraine sufferers. The market can be segmented by type of therapeutic class of drugs involved in the treatment and geography. The major antimigraine drugs used against migraine includes the drugs belonging to the class, triptans such as Sumatriptan, Zolmitriptan, and others. Major factors influencing the growth of this market is the consistent rise in the incidence rates of migraine cases, increased acceptance levels, increased awareness and technological advances in the development of anti-migraine drugs. 

On the other hand patent expirations, high genericization and emergence of local players may mask the growth of the market. Some of the major market players of this market are Abbott Laboratories, Inc. Eisai, Inc., Eli Lilly and Company, Pfizer, Inc., AstraZeneca plc, and GlaxoSmithKline plc.

 More reports on Pharmaceuticals market: 
http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include 
  • North America 
  • Asia Pacific 
  • Europe
  • Rest of the World  
This report provides comprehensive analysis of 
  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for upcoming years 
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

About Us:

Transparency Market Research (TMR) is a market intelligence company providing global business research reports and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers.

TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources along with various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information which is indispensable for businesses to sustain their competitive edge.

Contact Us:

CORPORATE OFFICE:
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States

Tel: +1-518-618-1030

Read More

Tuesday, 3 September 2013

Erectile Dysfunction Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast (2013 - 2019)

21:49 No comments
Erectile dysfunction (ED) is one of the most common sexual problems of men and the susceptibility to this condition increases with aging. The most likely causes of ED are effects of certain medications (anti-depressants and nicotine), chronic diseases (cardiovascular and diabetes), kidney failure, stressful life style and aging. Poor health, obesity, smoking and poor dietary habits may also cause ED. Hesitation in discussing this condition with physicians has resulted in a large pool of untreated patients. There is no gold standard test to identify ED and is usually diagnosed by going through medical history of the patient, a few physical tests and blood tests. Some blood tests are carried out to exclude underlying causes such as diabetes, high cholesterol level and cardiovascular diseases.


The first line therapy for the treatment of ED is use of phosphodiesterase-5 inhibitors (PDE-5) such as sidenafil, tadalafil and vardenafil. These drugs act by augmenting the effect of nitric oxide that relaxes penile muscles and ensures proper blood flow and allows erection. The use of these drugs is contraindicated when a patient is already taking nitrate drugs, anticoagulants and if he is suffering from cardiovascular diseases and diabetes. Viagra (Pfizer), Cialis (Eli Lilly) and Levitra (Bayer) are the leading brand names in this segment.

The market for erectile dysfunction drugs is growing worldwide due to the rapidly increasing prevalence of ED and is predicted to be doubled by the end of 2025. At present, North America represents the largest market for these drugs due to the existence of large number of population affected with ED and high awareness about healthcare and wellbeing. The Urology Care Foundation, an official foundation of the American Urological Association, estimates that at present an average of 15 to 30 million people are suffering from ED across the country with varying levels of distress. The Massachussetts Male Ageing Study suggests that more than 50% of men aged over 40 years of age experience some degree of ED. 

Asia-Pacific represents a potential market for erectile dysfunction drugs due to growing aging population. One of the other factors expected to drive the market in Asia-Pacific region is increasing awareness about the disease and improvement in healthcare infrastructure.

Some of the prominent players operating in this market space are Pfizer, Inc., Eli Lilly, Bayer Healthcare, Johnson & Johnson, GlaxoSmithKline, Sanofi, Astellas Pharma, Inc. and Merck & Co.

More reports on Pharmaceuticals market: 
http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include 
  • North America 
  • Asia Pacific 
  • Europe
  • Rest of the World  
This report provides comprehensive analysis of 
  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for upcoming years 
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

About Us:

Transparency Market Research (TMR) is a market intelligence company providing global business research reports and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers.

TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources along with various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information which is indispensable for businesses to sustain their competitive edge.

Contact Us:

CORPORATE OFFICE:
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States

Tel: +1-518-618-1030

Read More

Friday, 30 August 2013

Dyslipidemia Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast (2013 - 2019)

02:30 No comments
Dyslipidemia is a lipoprotein metabolism disorder characterized by abnormal amount of lipoprotein (LDL and HDL) concentrations in blood. It is usually caused by genetic factors, secondary factors or a combination of both kinds of factors. High density lipoproteins (HDL) are also known as good cholesterol and higher levels of these help reduce the risk of cardiovascular diseases. Higher levels of low density lipoproteins (LDL) or bad cholesterol are associated with the risk of heart attacks and strokes. 


The abnormal levels of cholesterol and triglycerides are capable of producing three forms of dyslipidemia namely, hypertriglyceridemia, hypercholesterolemia and a combination of both. Dyslipidemia is one of the major causes for the occurrence of cardiovascular diseases. Appropriate drug therapy against dyslipidemia can be selected based on the detection of varying concentrations of specific lipoproteins in the blood. The treatment approach adopted by physicians starts with non-drug interventions, which includes lifestyle modifications and exercise followed by pharmacotherapy which includes the use of lipid lowering drugs. 

The seven major classes of lipid lowering drugs used in the treatment of dyslipidemia are bile-acid sequestrants, nicotinic acid, HMG-CoA reductase inhibitors (statins), cholesterol modulators, fibric acid derivatives, cholesterol absorption inhibitors and combination products. Statins are the most widely used drugs to treat dyslipidemia. The dyslipidemia market can be segmented by the various drug classes mentioned above and by geography.  

The major factors influencing the growth of this market are sedentary lifestyle, higher inclination towards junk food, increasing incidence of cardiovascular diseases across the globe and associated risks. Patent expirations and high genericization may mask the growth of this market. With the patent expiration of Pfizer’s Lipitor, Merck’s Zocor and Bristol-Myers Squibb’s Pravachol, the dyslipidemia market is expected to experience a decline in sales of branded formulations and in turn decline in overall growth of this market. Some of the major players in this market are Pfizer, Inc., Merck & Co, Inc., Bristol-Myers Squibb, Novartis AG, AstraZeneca PLC and Abbott Laboratories. 
More reports on Pharmaceuticals market:

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include 
  • North America 
  • Asia Pacific 
  • Europe
  • Rest of the World  
This report provides comprehensive analysis of 
  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for upcoming years 
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

About Us:

Transparency Market Research (TMR) is a market intelligence company providing global business research reports and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers.

TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources along with various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information which is indispensable for businesses to sustain their competitive edge.

Contact Us:

CORPORATE OFFICE:
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States

Tel: +1-518-618-1030

Read More

Wednesday, 28 August 2013

Bioterrorism Detection Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast (2013 - 2019)

21:43 No comments
Bioterrorism refers to form of terrorism that involves intentional dissemination or release of biological agents. The agents can be viruses, bacteria or toxins and can also be referred to as germ warfare. Biological agents are mainly found in nature but sometimes they can be modified by the terrorist as to make agents more toxic. Biological agents are used by the terrorists to attain their social or political goals and are used for killing or injuring people, plants and animals. Biological weapons are dangerous as some of these agents are transmitted from one person to another and infection might take hours or days to become noticeable.

Browse full report at: http://www.transparencymarketresearch.com/bioterrorism-detection-market.html

Bioterrorism is an invaluable tool as biological agents are relatively inexpensive and can cause widespread fear beyond the actual damage they can cause. They are mainly used by the terrorists to create mass panic and disruption of state or economy. The global market for bioterrorism is segmented on the type of different biological agents currently being used and their mode of delivery.  Agents such as anthrax, tularemia, small pox, bubonic plague, botulinum toxin and viral hemorrhagic fevers pose a high threat to national security. 

Another category involves toxins such as typhus, glanders, Q fever, viral encephalitis and others poses moderate threat and involves low mortality. Last category involves emerging toxins that are engineered for mass dissemination, high mortality rate and ability to cause major health impact. Hantavirus, Nipah Virus, SARS, HIV/AIDS and H1N1 virus falls under this above mentioned category. The mode of delivery of these biological agents can be via aerosol dissemination, water contamination, food contamination, insect vectors and others.

However, federal government supports many programs and researches but it does not provide any direct protection against bioterrorists attacks for many important buildings. These buildings include theaters, shopping centers, large buildings and others. In the United States virtually all these buildings remain susceptible to bioterrorist attack. Key protection to these facilities involves the presence of warning systems which provide immediate response to such attacks.

Some of the major players that provide and bioterrorism defense products are Acambis Plc, Evogen, Inc., Human Genome Sciences, ICX Technologies, Inc., PharmAthene, Inc. and others.

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include 
  • North America 
  • Asia Pacific 
  • Europe
  • Rest of the World  
This report provides comprehensive analysis of 
  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for upcoming years 
More reports on Pharmaceuticals market: 

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

About Us:

Transparency Market Research (TMR) is a market intelligence company providing global business research reports and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers.

TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources along with various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information which is indispensable for businesses to sustain their competitive edge.

Contact Us:

CORPORATE OFFICE:
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States

Tel: +1-518-618-1030

Read More

Global Blood Disease Treatment Drugs Market - Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

03:04 No comments
Blood comprises of red blood cells, white blood cells, plasma and platelets. Sometimes, people might be affected with different types of blood disorders and blood cancers due to aging, infections, exposure to certain chemicals, smoking, genetic disorders and other factors. Hence, the category of blood disorders is wide and numerous types of diseases fall under it. 

Browse full report at: http://www.transparencymarketresearch.com/blood-disease-treatment-drugs.html

There are three main types of cancer that affect blood namely leukemia which affects the bone marrow and is caused by abnormal production of white blood cells. Myeloma is a type of blood cancer that affects plasma cells whereas lymphoma is a cancer that affects the lymphatic system. The diseases that affect white blood cells are mainly lymphoma and leukemia and  anemia, sickle cell anemia and polycythemia diseases are mainly affecting red blood cells. Diseases such as heparin, thrombocytopenia and essential thrombocytosis affect the platelets found in blood and hemophilia and sepsis affect blood plasma. 

Hematological cancers represent a significant problem globally. Every year more than 100,000 cases of blood cancers are diagnosed in United States and more than 50,000 people die from such cancer cases. Many specific therapies for the treatment of cancers have been developed that include biologics and small-molecule drug therapies. Leukemia accounts for the ninth most common occurring cancer in males across the globe. Leukemia market is segmented into four types that include acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, and chronic myeloid leukemia. Thus, with the rise in number of cancer cases the market in future is projected to grow. 

Drugs such as Sprycel, Arranon, Clolar, Gleevec, Quizartinib, Marqibo, and Tasigna are the major drugs available for the treatment of leukemia. The blood diseases treatment drugs market is witnessing competition among the players with drugs in pipeline for early diagnosis and treatment of blood disorders.  

Some of the key players in the blood disease treatment drugs market include Novartis International AG, Celgene Corporation, Pfizer, GlaxoSmithKline Pharmaceuticals, Ambit Bioscience and other major players.

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include 
  • North America 
  • Asia Pacific 
  • Europe
  • Rest of the World  
This report provides comprehensive analysis of 
  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for upcoming years 
More reports on Pharmaceutical market:

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

About Us:

Transparency Market Research (TMR) is a market intelligence company providing global business research reports and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers.

TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources along with various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information which is indispensable for businesses to sustain their competitive edge.

Contact Us:

CORPORATE OFFICE:
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States

Tel: +1-518-618-1030

Read More
Subscribe to: Posts (Atom)